Neos Therapeutics Inc. (NASDAQ:NEOS) has received a consensus rating of “Buy” from the five research firms that are covering the stock. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $30.50.
A number of research firms have issued reports on NEOS. BMO Capital Markets reiterated a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, September 20th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Thursday, October 13th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NEOS. Wells Fargo & Company MN acquired a new position in Neos Therapeutics during the third quarter worth $139,000. Schwab Charles Investment Management Inc. acquired a new position in Neos Therapeutics during the second quarter worth $200,000. Bridgeway Capital Management Inc. acquired a new position in Neos Therapeutics during the second quarter worth $603,000. State Street Corp increased its position in Neos Therapeutics by 61.2% in the second quarter. State Street Corp now owns 104,530 shares of the company’s stock worth $972,000 after buying an additional 39,705 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock worth $126,000 after buying an additional 1,233 shares in the last quarter. Institutional investors and hedge funds own 34.32% of the company’s stock.
Shares of Neos Therapeutics (NASDAQ:NEOS) traded down 3.571% during midday trading on Monday, hitting $7.425. 36,107 shares of the stock were exchanged. The firm’s market cap is $119.25 million. The stock’s 50 day moving average is $6.81 and its 200 day moving average is $7.99. Neos Therapeutics has a 12-month low of $5.30 and a 12-month high of $16.41.